ARID2 is a pomalidomide-dependent CRL4<sup>CRBN</sup> substrate in multiple myeloma cells

September 21st, 2020 by Junichi Yamamoto

Nature Chemical Biology, Published online: 21 September 2020; doi:10.1038/s41589-020-0645-3

Immunomodulatory drugs are used for the treatment of multiple myeloma. ARID2, a component of the PBAF chromatin-remodeling complex, is a new pomalidomide-induced neosubstrate of CRL4CRBN, which accounts for its superior efficacy over lenalidomide.
  • Posted in Nat Chem Biol, Publications
  • Comments Off on ARID2 is a pomalidomide-dependent CRL4<sup>CRBN</sup> substrate in multiple myeloma cells